Nipro FCF Margin
The Free Cash Flow Margin of Nipro (8086.T) as of Jul 24, 2026 is -1.25 %. In the previous year, Free Cash Flow Margin was -3.62 % — a change of -65.62% (higher).
Get this data via API
Financial Data API
FCF Margin
-1.25 %
YoY
-65.62%
Last updated:
Free Cash Flow Margin of Nipro is 2026 -1.25 % . Free Cash Flow Margin of Nipro was 2025 -3.62 % . It decreases by -65.62% higher compared to the previous year.
Access this data via the Eulerpool API
Nipro Stock analysis
What does Nipro do? Nipro Corp is a Japanese company that was originally founded under the name Niki Shoji. The company was established in 1954 and initially produced steel pipes and accessories. In 1964, the company changed its name to Nipro Corp and expanded its business to the production of medical devices and instruments. Since then, Nipro Corp has become a major player in the global market for medical products and services.
The business model of Nipro Corp is based on the design, manufacturing, and sale of a wide range of medical products, including dialysis machines, artificial organs, blood glucose meters, and infusion devices. The company is also active in the pharmaceutical and healthcare industries, offering various related services such as clinical trials.
Nipro Corp is divided into various divisions, including Nipro Medical Corporation, which produces and sells the company's medical product range. This division is divided into three departments: dialysis technology, transfusion and infusion department, and the artificial organs department, which includes various products such as heart-lung machines and artificial kidneys.
Another important division is Nipro Pharma Corporation, which focuses on the development, manufacturing, and sale of pharmaceuticals. The company has a strong presence in this division in the Asian market and is currently expanding into Europe and the United States.
Another important area in which Nipro Corp is active is the manufacturing of glass and plastic products, particularly glass ampoules for storing medications and plastic products for medical use.
In addition to its main business areas, Nipro Corp also offers a wide range of products and services for environmental technology, the semiconductor industry, and the electronics industry. The company is also involved in the production of solar energy products and has filed various patents in this field.
Innovation and quality control are two important focuses of Nipro Corp. The company is heavily dedicated to researching and developing new products and technologies, as well as building strong business relationships with its customers. One of the key strategies of the company is to align its research and development activities with the needs of its customers and end-users to ensure that its products meet their requirements and expectations.
Another focus of Nipro Corp is quality assurance and control. The company has a strict quality management system that is applied in all stages of the manufacturing process to ensure that its products meet the highest international standards.
Overall, Nipro Corp has become a major player in the global market for medical products and services. With its wide range of products and services, focus on innovation and quality, and strong presence in the Asian market, the company is in a strong position to continue growing and evolving.
Nipro is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Nipro stock
Free Cash Flow Margin of Nipro is -1.25 % in 2026.
Access this data via the Eulerpool API
Margins — Nipro
All Key Metrics — Nipro
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth